Developing an understanding of disease progression in MDS and AML

From MDS to AML: Understanding the Pathology, Diagnostics, and Genetic Relationship 10/10/17Подробнее

Managing the progression of MDS to AMLПодробнее

MDS as an Immunoresponsive DiseaseПодробнее

MDS: Understanding Disease Characteristics and ProgressionПодробнее

Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Подробнее

Use of Molecular Genetic Testing in MDS and MPNПодробнее

MDS/AML Overlap and Novel Therapies with Dr. Naval DaverПодробнее

MDS: Understanding Disease Characteristics and ProgressionПодробнее

The Myelodysplastic Syndrome - Past is Prologue: Insight to Personalized TherapyПодробнее

Understanding Higher Risk MDS and Transtion to AMLПодробнее

Biology of AML Developing from MDS vs. de Novo AML, and New Targets for TherapyПодробнее

Advancing the management of MDS and AML: Novel immune-based approachesПодробнее

How do you distinguish between a diagnosis of MDS and AML? #AMLПодробнее

Understanding AMLПодробнее

What’s the connection between myelodysplastic syndrome (MDS) and AML-MRC?Подробнее

Understanding Myelodysplastic Syndrome’s Nature as CancerПодробнее

Innovations in MDS and AML treatmentПодробнее

Epigenetic mechanisms driving the progression of MDS to secondary AMLПодробнее

How serious a cancer is MDS? What is the prognosis for MDS?Подробнее

Understanding genetic and non-genetic mechanisms involve in AML disease progressionПодробнее

Updates from ASH 2020: Promising Treatment Advances for MDS and AMLПодробнее

Factors driving the transformation of CHIP to MDSПодробнее